Live Love Life Hosts Largest National HIV Testing Day Event Across Central and Northeast Florida
Live Love Life Community Health Care Clinics will host its largest outreach effort to date, offering free, walk-in HIV testing at multiple locations.
HOLLY HILL, FL, UNITED STATES, June 27, 2025 / EINPresswire.com / -- In recognition of National HIV Testing Day on Friday, June 27, Live Love Life Community Health Care Clinics will host its largest outreach effort to date, offering free, walk-in HIV testing at multiple locations across Central and Northeast Florida. The event will take place from 10:00 a.m. to 6:30 p.m., providing residents with a simple, fast, and confidential way to know their status and access supportive care.
The testing sites will be located at the Live Love Life Clinic in Holly Hill. In addition, testing will be available at three off-site Walgreens and pharmacy locations: Walgreens #7241 in Deltona, Walgreens #4441 in Daytona Beach, and PHD Pharmacy in Orlando. All locations will offer free rapid HIV tests, with no appointments necessary, and results are available in minutes.
'At Live Love Life, we believe health equity begins wherever people are; not just inside a clinic,' says Mark Walczyk, CEO of Live Love Life. 'That's why today, we're meeting our community where they live, work, and gather; with free STI, HIV, and hepatitis C testing, health education, and real pathways to care. We invite everyone—whether you're curious, concerned, or simply care about your health - to stop by, bring a friend, and take one small step toward something better. Because this is more than public health, this is public love.'
National HIV Testing Day is a critical moment to increase awareness around HIV prevention, testing, and treatment. Early diagnosis not only improves health outcomes but also plays a vital role in preventing the spread of HIV within the community. Through this event, Live Love Life aims to empower individuals to take charge of their health and encourage open conversations about testing and care.
Beyond HIV testing, Live Love Life Clinics offer a wide range of inclusive health services year-round. These include hepatitis C testing and treatment, harm reduction support, PrEP and PEP education, LGBTQIA+ affirming care, and assistance with insurance enrollment and benefits navigation. The organization has established clinics in Holly Hill, Daytona, Ormond Beach, Deland, Orlando (Pine Hills and Universal), and Jacksonville (Downtown and Southside), with additional locations in development.
Community members are encouraged to attend, bring friends or loved ones, and help spread the word about this life-saving initiative. No registration is required—just walk in and get tested.
For more information about Live Love Life, please visit https://www.livelovelife.care/.
Charlie Walker
Live Love Life
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
17 hours ago
- Yahoo
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
The Hill
a day ago
- The Hill
Obamacare preventive care mandate wins in Supreme Court ruling
The Big Story The Supreme Court on Friday upheld a key Affordable Care Act requirement that insurance companies cover certain preventative measures recommended by an expert panel. © AP Justices upheld the constitutionality of the provision in a 6-3 decision and protected access to preventative care for about 150 million Americans. The justices found that the secretary of the Department of Health and Human Services has the power to appoint and fire members of the U.S. Preventative Services Task Force (USPSTF). The cases started when a small business in Texas and some individuals filed a lawsuit against the panel's recommendation that pre-exposure prophylaxis (PreP) for HIV be included as a preventative care service. They argued that covering PreP went against their religious beliefs and would 'encourage homosexual behavior, intravenous drug use, and sexual activity outside of marriage between one man and one woman.' The plaintiffs further argued that the USPSTF mandates are unconstitutional because panel members are 'inferior officers' who are not appointed by the president or confirmed by the Senate. While the panel is independent, they said that since their decisions impact millions of people members should be confirmed. A U.S. district judge in 2023 ruled that all preventative-care coverage imposed since the ACA was signed into law are invalid and a federal appeals court judge ruled in agreement last year. The Biden administration appealed the rulings to the Supreme Court, and the Trump administration chose to defend the law despite its long history of disparaging Obamacare. Though public health groups celebrated the ruling Friday, some noted another potential outcome. 'While this is a foundational victory for patients, patients have reason to be concerned that the decision reaffirms the ability of the HHS secretary, including our current one, to control the membership and recommendations of the US Preventive Services Task Force that determines which preventive services are covered,' Anthony Wright, executive director of Families USA, said in a statement. 'We must be vigilant to ensure Secretary Kennedy does not undo coverage of preventive services by taking actions such as his recent firing of qualified health experts from the CDC's independent vaccine advisory committee and replacing them with his personal allies.' Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Joseph Choi and Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: New Hampshire lawmakers give final approval to gender-affirming care ban New Hampshire lawmakers on Thursday gave final approval to bills that would ban gender-affirming care for transgender minors in the state, sending the measures to Republican Gov. Kelly Ayotte, who has not yet said whether she will sign them. State lawmakers voted to pass House Bill 377, which would prohibit doctors from administering puberty blockers and hormones to transgender youth beginning next year. The measure includes … FDA expanding COVID vaccine warnings over rare heart side effect The U.S. Food and Drug Administration is now requiring two common COVID-19 vaccines to update their warning labels to include information on two rare heart side effects. Myocarditis, or inflammation of the heart muscle, and pericarditis, or inflammation of the thin sac surrounding the heart — are two conditions that a small number of people have experienced after receiving the mRNA COVID-19 shot. The rare cases of myocarditis … What causes a stroke? Learn the triggers and risk factors Most Americans likely know at least a little about the signs of a stroke. While early intervention is vital for a positive outcome, medical experts also stress the need to prevent strokes, which the Stroke Foundation reports are the fifth leading cause of death in the U.S. The key to prevention is knowing what causes these brain attacks. According to the American Heart Association, a stroke occurs when a blood vessel to the … In Other News Branch out with a different read from The Hill: GOP leader sets Saturday vote on Trump 'big, beautiful bill' despite Republican pushback Senate Majority Leader John Thune (R-S.D.) told Senate Republicans to expect to see the legislative text of the budget reconciliation package on Friday evening and then to vote at noon Saturday to begin debate on President Trump's tax and spending bill. Around the Nation Local and state headlines on health care: What We're Reading Health news we've flagged from other outlets: What Others are Reading Most read stories on The Hill right now: GOP leader sets Saturday vote on Trump 'big, beautiful bill' despite Republican pushback Senate Majority Leader John Thune (R-S.D.) told Senate Republicans to expect to see the legislative text of the budget reconciliation package on Friday … Read more 5 takeaways from the Supreme Court's birthright citizenship ruling The Supreme Court handed President Trump a clear victory Friday, stopping judges from issuing nationwide injunctions that block his executive order … Read more What People Think Opinions related to health submitted to The Hill: Thank you for signing up! Subscribe to more newsletters here
